Hiv Treatment Articles & Analysis
14 news found
Hao Yang, President of China Association for STD and AIDS Prevention and Treatment; Mrs. Wang Xinlun, Vice President and Secretary-General of China Association for STD and AIDS Prevention and Treatment, industry experts and representatives of partner companies and institutions attended the ceremony. Since China initiated antiretroviral treatment ...
"We have witnessed many successful cases of compound docking applications in drugs for the treatment of HIV, cancers, and other prevalent diseases. The technical details refer to docking algorithms, Cresset software, other relevant computational methods, etc., which in combination make up our comprehensive service package," commented a senior scientist of BOC ...
Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual therapy to treat people living with HIV who have ...
Continued the recruitment for two Phase 2 clinical trials of BIT225 for treatment of HIV-1 infection at sites in Australia and Thailand. Continued the design, synthesis and testing of new compounds under its HIV-1 program, with the aim of identifying a next generation lead anti-HIV-1 drug. ...
Anastasia Batrak, Vice President of strategic marketing and product portfolio development at R-Pharm, said, “The drug-resistant strains of HIV are a serious threat to public safety. In Russia, 6-7% of newly treated patients have HIV resistance. ...
The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting HIV-1 fusion inhibitor, Aikening® (generic name: Albuvirtide [ABT]) in ...
OB-002, a highly potent chemokine analog of CCL5 (a ligand for the CCR5 HIV co-receptor), has previously been shown to be completely protective in a non-human primate model of vaginal HIV transmission (Veazey R et al. ...
Orion plans to submit the study data to the HIVR4P HIV prevention meeting which will be held in Cape Town South Africa in January 2021 (https://www.hivr4p.org/). ...
Tenofovir is one of the most frequently used antiretroviral drugs in the multi-drug treatment of HIV infection. However, since tenofovir does not cross the BBB following systemic administration, the treatment is not effective against viral reservoirs in the central nervous system (CNS). The persistence of HIV in the CNS (called ...
Delayed test results often mean HIV patients in Mozambique fail to get timely treatment, but new technology is reducing the need to send tests to far away laboratories, and speeding up test results and HIV treatment. ...
Today about 90 percent of Batswana living with HIV receive treatment, compared to less than 5 percent when the program began in 2001. ...
People Encouraging People of Baltimore was awarded a $150,000 grant to support Project OPEN, a mobile treatment service offered to people at high risk of contracting HIV/AIDS or who have lost coverage for their HIV/AIDS treatment. ...
ViiV Healthcare is seeking letters of interest (LOIs) to support programs specifically focused on reducing disparities in HIV/AIDS linkages to care and treatment among African American and Latinos in Alabama, Georgia, Louisiana and Mississippi. ...
However, access to care and treatment for HIV-positive children remains woefully inadequate in many of these environments. The partnership between ViiV Healthcare and the Elizabeth Glaser Pediatric AIDS Foundation specifically addresses critical gaps in current HIV/AIDS prevention, care, and treatment programs. Despite available ...